prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-ons...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2009-04, Vol.114 (3), p.457-462
Hauptverfasser: Cao, A-Yong, Huang, Juan, Hu, Zhen, Li, Wen-Feng, Ma, Zhong-Liang, Tang, Li-Li, Zhang, Bin, Su, Feng-Xi, Zhou, Jie, Di, Gen-Hong, Shen, Kun-Wei, Wu, Jiong, Lu, Jin-Song, Luo, Jian-Min, Yuan, Wen-Tao, Shen, Zhen-Zhou, Huang, Wei, Shao, Zhi-Ming
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 462
container_issue 3
container_start_page 457
container_title Breast cancer research and treatment
container_volume 114
creator Cao, A-Yong
Huang, Juan
Hu, Zhen
Li, Wen-Feng
Ma, Zhong-Liang
Tang, Li-Li
Zhang, Bin
Su, Feng-Xi
Zhou, Jie
Di, Gen-Hong
Shen, Kun-Wei
Wu, Jiong
Lu, Jin-Song
Luo, Jian-Min
Yuan, Wen-Tao
Shen, Zhen-Zhou
Huang, Wei
Shao, Zhi-Ming
description PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C>T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C>T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.
doi_str_mv 10.1007/s10549-008-0036-z
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66965426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66965426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-c0d7841bbe092f46e28d6929b3d2b506cb5a93f3f8fb760852dfe230275873a23</originalsourceid><addsrcrecordid>eNp9kUlvFDEQhS0EIkPgB3ABKxLcmpSX9nKcjNikkUBAzpa7uzzpqJfB7k6U3PjneOgRkThwcPlQ33tVqkfISwbvGIA-TwxKaQsAk59Qxf0jsmKlFoXmTD8mK2BKF8qAOiHPUroGAKvBPiUnzEippFAr8msf8cZ3ONRIx0C_rrcXnO4w9l07IO3nyU_tOCTaDvTi22bNzg-V0wF3uXGDdHOVuYT0duxxoLftdEXRx-6OZhFOtIro00Rrn_0jHSP1IWA9YUMjdn8c0nPyJPgu4Yvjf0ouP7z_sflUbL98_LxZb4tacjEVNTTaSFZVCJYHqZCbRlluK9HwqgRVV6W3IohgQqUVmJI3AbkArkujhefilLxdfPdx_Dljmlzfphq7zg84zskpZVUpucrg2T_g9TjHIe_mOOPSSJAsQ2yB6jimFDG4fWx7H-8cA3cIxy3huByOO4Tj7rPm1dF4rnpsHhTHNDLw5gj4VPsuxHy2Nv3l8nTOjRWZ4wuXcmvIaT1s-L_prxdR8KPzu5iNL79zYAJYaa3gpfgNmAKvpw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212484041</pqid></control><display><type>article</type><title>prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Cao, A-Yong ; Huang, Juan ; Hu, Zhen ; Li, Wen-Feng ; Ma, Zhong-Liang ; Tang, Li-Li ; Zhang, Bin ; Su, Feng-Xi ; Zhou, Jie ; Di, Gen-Hong ; Shen, Kun-Wei ; Wu, Jiong ; Lu, Jin-Song ; Luo, Jian-Min ; Yuan, Wen-Tao ; Shen, Zhen-Zhou ; Huang, Wei ; Shao, Zhi-Ming</creator><creatorcontrib>Cao, A-Yong ; Huang, Juan ; Hu, Zhen ; Li, Wen-Feng ; Ma, Zhong-Liang ; Tang, Li-Li ; Zhang, Bin ; Su, Feng-Xi ; Zhou, Jie ; Di, Gen-Hong ; Shen, Kun-Wei ; Wu, Jiong ; Lu, Jin-Song ; Luo, Jian-Min ; Yuan, Wen-Tao ; Shen, Zhen-Zhou ; Huang, Wei ; Shao, Zhi-Ming</creatorcontrib><description>PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C&gt;T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C&gt;T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-008-0036-z</identifier><identifier>PMID: 18446436</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Boston : Springer US</publisher><subject>Adult ; Age of Onset ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Breast cancer ; breast neoplasms ; Breast Neoplasms - epidemiology ; Breast Neoplasms - genetics ; Cancer research ; Cancer therapies ; China ; Chinese ; DHPLC ; Family Health ; Fanconi Anemia Complementation Group N Protein ; Female ; General aspects (metabolism, cell proliferation, established cell line...) ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic disorders ; Germ-Line Mutation ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Mutation ; Nuclear Proteins - genetics ; Oncology ; PALB2 ; Population genetics ; Preclinical Study ; Prevalence ; Sequence variation ; Tumor cell ; Tumor Suppressor Proteins - genetics ; Tumors</subject><ispartof>Breast cancer research and treatment, 2009-04, Vol.114 (3), p.457-462</ispartof><rights>Springer Science+Business Media, LLC. 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC. 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-c0d7841bbe092f46e28d6929b3d2b506cb5a93f3f8fb760852dfe230275873a23</citedby><cites>FETCH-LOGICAL-c423t-c0d7841bbe092f46e28d6929b3d2b506cb5a93f3f8fb760852dfe230275873a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-008-0036-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-008-0036-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21222893$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18446436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, A-Yong</creatorcontrib><creatorcontrib>Huang, Juan</creatorcontrib><creatorcontrib>Hu, Zhen</creatorcontrib><creatorcontrib>Li, Wen-Feng</creatorcontrib><creatorcontrib>Ma, Zhong-Liang</creatorcontrib><creatorcontrib>Tang, Li-Li</creatorcontrib><creatorcontrib>Zhang, Bin</creatorcontrib><creatorcontrib>Su, Feng-Xi</creatorcontrib><creatorcontrib>Zhou, Jie</creatorcontrib><creatorcontrib>Di, Gen-Hong</creatorcontrib><creatorcontrib>Shen, Kun-Wei</creatorcontrib><creatorcontrib>Wu, Jiong</creatorcontrib><creatorcontrib>Lu, Jin-Song</creatorcontrib><creatorcontrib>Luo, Jian-Min</creatorcontrib><creatorcontrib>Yuan, Wen-Tao</creatorcontrib><creatorcontrib>Shen, Zhen-Zhou</creatorcontrib><creatorcontrib>Huang, Wei</creatorcontrib><creatorcontrib>Shao, Zhi-Ming</creatorcontrib><title>prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C&gt;T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C&gt;T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.</description><subject>Adult</subject><subject>Age of Onset</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>breast neoplasms</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - genetics</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>China</subject><subject>Chinese</subject><subject>DHPLC</subject><subject>Family Health</subject><subject>Fanconi Anemia Complementation Group N Protein</subject><subject>Female</subject><subject>General aspects (metabolism, cell proliferation, established cell line...)</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Genetic disorders</subject><subject>Germ-Line Mutation</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Nuclear Proteins - genetics</subject><subject>Oncology</subject><subject>PALB2</subject><subject>Population genetics</subject><subject>Preclinical Study</subject><subject>Prevalence</subject><subject>Sequence variation</subject><subject>Tumor cell</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUlvFDEQhS0EIkPgB3ABKxLcmpSX9nKcjNikkUBAzpa7uzzpqJfB7k6U3PjneOgRkThwcPlQ33tVqkfISwbvGIA-TwxKaQsAk59Qxf0jsmKlFoXmTD8mK2BKF8qAOiHPUroGAKvBPiUnzEippFAr8msf8cZ3ONRIx0C_rrcXnO4w9l07IO3nyU_tOCTaDvTi22bNzg-V0wF3uXGDdHOVuYT0duxxoLftdEXRx-6OZhFOtIro00Rrn_0jHSP1IWA9YUMjdn8c0nPyJPgu4Yvjf0ouP7z_sflUbL98_LxZb4tacjEVNTTaSFZVCJYHqZCbRlluK9HwqgRVV6W3IohgQqUVmJI3AbkArkujhefilLxdfPdx_Dljmlzfphq7zg84zskpZVUpucrg2T_g9TjHIe_mOOPSSJAsQ2yB6jimFDG4fWx7H-8cA3cIxy3huByOO4Tj7rPm1dF4rnpsHhTHNDLw5gj4VPsuxHy2Nv3l8nTOjRWZ4wuXcmvIaT1s-L_prxdR8KPzu5iNL79zYAJYaa3gpfgNmAKvpw</recordid><startdate>20090401</startdate><enddate>20090401</enddate><creator>Cao, A-Yong</creator><creator>Huang, Juan</creator><creator>Hu, Zhen</creator><creator>Li, Wen-Feng</creator><creator>Ma, Zhong-Liang</creator><creator>Tang, Li-Li</creator><creator>Zhang, Bin</creator><creator>Su, Feng-Xi</creator><creator>Zhou, Jie</creator><creator>Di, Gen-Hong</creator><creator>Shen, Kun-Wei</creator><creator>Wu, Jiong</creator><creator>Lu, Jin-Song</creator><creator>Luo, Jian-Min</creator><creator>Yuan, Wen-Tao</creator><creator>Shen, Zhen-Zhou</creator><creator>Huang, Wei</creator><creator>Shao, Zhi-Ming</creator><general>Boston : Springer US</general><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20090401</creationdate><title>prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives</title><author>Cao, A-Yong ; Huang, Juan ; Hu, Zhen ; Li, Wen-Feng ; Ma, Zhong-Liang ; Tang, Li-Li ; Zhang, Bin ; Su, Feng-Xi ; Zhou, Jie ; Di, Gen-Hong ; Shen, Kun-Wei ; Wu, Jiong ; Lu, Jin-Song ; Luo, Jian-Min ; Yuan, Wen-Tao ; Shen, Zhen-Zhou ; Huang, Wei ; Shao, Zhi-Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-c0d7841bbe092f46e28d6929b3d2b506cb5a93f3f8fb760852dfe230275873a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Age of Onset</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>breast neoplasms</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - genetics</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>China</topic><topic>Chinese</topic><topic>DHPLC</topic><topic>Family Health</topic><topic>Fanconi Anemia Complementation Group N Protein</topic><topic>Female</topic><topic>General aspects (metabolism, cell proliferation, established cell line...)</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Genetic disorders</topic><topic>Germ-Line Mutation</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Nuclear Proteins - genetics</topic><topic>Oncology</topic><topic>PALB2</topic><topic>Population genetics</topic><topic>Preclinical Study</topic><topic>Prevalence</topic><topic>Sequence variation</topic><topic>Tumor cell</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, A-Yong</creatorcontrib><creatorcontrib>Huang, Juan</creatorcontrib><creatorcontrib>Hu, Zhen</creatorcontrib><creatorcontrib>Li, Wen-Feng</creatorcontrib><creatorcontrib>Ma, Zhong-Liang</creatorcontrib><creatorcontrib>Tang, Li-Li</creatorcontrib><creatorcontrib>Zhang, Bin</creatorcontrib><creatorcontrib>Su, Feng-Xi</creatorcontrib><creatorcontrib>Zhou, Jie</creatorcontrib><creatorcontrib>Di, Gen-Hong</creatorcontrib><creatorcontrib>Shen, Kun-Wei</creatorcontrib><creatorcontrib>Wu, Jiong</creatorcontrib><creatorcontrib>Lu, Jin-Song</creatorcontrib><creatorcontrib>Luo, Jian-Min</creatorcontrib><creatorcontrib>Yuan, Wen-Tao</creatorcontrib><creatorcontrib>Shen, Zhen-Zhou</creatorcontrib><creatorcontrib>Huang, Wei</creatorcontrib><creatorcontrib>Shao, Zhi-Ming</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, A-Yong</au><au>Huang, Juan</au><au>Hu, Zhen</au><au>Li, Wen-Feng</au><au>Ma, Zhong-Liang</au><au>Tang, Li-Li</au><au>Zhang, Bin</au><au>Su, Feng-Xi</au><au>Zhou, Jie</au><au>Di, Gen-Hong</au><au>Shen, Kun-Wei</au><au>Wu, Jiong</au><au>Lu, Jin-Song</au><au>Luo, Jian-Min</au><au>Yuan, Wen-Tao</au><au>Shen, Zhen-Zhou</au><au>Huang, Wei</au><au>Shao, Zhi-Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2009-04-01</date><risdate>2009</risdate><volume>114</volume><issue>3</issue><spage>457</spage><epage>462</epage><pages>457-462</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C&gt;T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C&gt;T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.</abstract><cop>Boston</cop><pub>Boston : Springer US</pub><pmid>18446436</pmid><doi>10.1007/s10549-008-0036-z</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-6806
ispartof Breast cancer research and treatment, 2009-04, Vol.114 (3), p.457-462
issn 0167-6806
1573-7217
language eng
recordid cdi_proquest_miscellaneous_66965426
source MEDLINE; SpringerNature Journals
subjects Adult
Age of Onset
Aged
Aged, 80 and over
Biological and medical sciences
Breast cancer
breast neoplasms
Breast Neoplasms - epidemiology
Breast Neoplasms - genetics
Cancer research
Cancer therapies
China
Chinese
DHPLC
Family Health
Fanconi Anemia Complementation Group N Protein
Female
General aspects (metabolism, cell proliferation, established cell line...)
Genes, BRCA1
Genes, BRCA2
Genetic disorders
Germ-Line Mutation
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Mutation
Nuclear Proteins - genetics
Oncology
PALB2
Population genetics
Preclinical Study
Prevalence
Sequence variation
Tumor cell
Tumor Suppressor Proteins - genetics
Tumors
title prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T15%3A46%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=prevalence%20of%20PALB2%20germline%20mutations%20in%20BRCA1/BRCA2%20negative%20Chinese%20women%20with%20early%20onset%20breast%20cancer%20or%20affected%20relatives&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Cao,%20A-Yong&rft.date=2009-04-01&rft.volume=114&rft.issue=3&rft.spage=457&rft.epage=462&rft.pages=457-462&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-008-0036-z&rft_dat=%3Cproquest_cross%3E66965426%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212484041&rft_id=info:pmid/18446436&rfr_iscdi=true